Early Phase 3 trials like JAVELIN adding immunotherapy to chemoradiation failed to improve outcomes. However, subgroup analyses consistently showed a potential benefit in PD-L1 high-expressing patients, a crucial lesson that informed the design of subsequent, more successful studies.

Unlike traditional cytotoxic agents, the DLL3-targeting T-cell engager tarlatumab demonstrates consistent overall survival benefits in third-line SCLC regardless of the patient's chemotherapy-free interval from first-line therapy. This indicates it works via a distinct mechanism that bypasses conventional chemoresistance pathways, representing a new treatment paradigm.

The novel target DLL3 is a promising avenue for treating NECs, but its therapeutic efficacy is highly dependent on expression levels. Early trial data for a DLL3 T-cell engager showed a 40% response rate in high-expressing tumors versus just 3% in low-expressors, mandating biomarker testing for patient selection.

The Keynote 942 study didn't just show clinical improvement; it demonstrated that the neoantigen vaccine expanded specific T-cell clones associated with positive patient response. This confirms the therapy's intended biological mechanism of action, a critical step for validating this new class of cancer treatment.

T-cell engagers (TCEs) are likely to be safer in autoimmune conditions than in cancer. Autoimmune patients have a relatively normal B-cell count, unlike the massive proliferation in hematologic cancers. This lower target cell burden naturally limits the scale of T-cell activation and inflammatory toxicity.

Despite widespread use in oncology, immunotherapy has limited efficacy in extrapulmonary NEC. Real-world data for combination CTLA-4 and PD-1 inhibitors show response rates around 15%, with sustained responses in less than 10% of patients. This highlights the urgent need for novel therapeutic approaches beyond checkpoint inhibition.

Early data from the Darien-7 trial shows combining the DLL3 T-cell engager Obrextamic with first-line chemotherapy achieves a near 75% response rate in EpNEC patients. Critically, it also extends the median duration of response to 8.8 months, more than double the historical average for chemotherapy alone, indicating a synergistic and highly durable effect.

While CAR-T therapy is known in blood cancers, engineered T-cell receptor (TCR) therapies are finding their first major successes in solid tumors within the sarcoma community. Treatments targeting MAGE-A4 and NY-ESO-1 in specific sarcomas are demonstrating high efficacy and leading development in the field.

While high DLL3 expression is a key predictor for most T-cell engagers, early data for the tri-specific antibody Gossetamic shows responses in both high and low DLL3 prostate neuroendocrine carcinomas. This suggests the biology of prostate NECs may differ, questioning if DLL3 expression is a universal biomarker for all extrapulmonary neuroendocrine carcinoma subtypes.